Subtype
Primary Central Nervous System Neoplasm
CI-CAN-00001432Explore in graph →
Non-malignant957 active trials5 approved drugs175 evidence items
- NCIt
- C102871
Loading cancer entity…
Subtype
CI-CAN-00001432Explore in graph →
Clinical trials
3,293 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05406947 | Establishment and Clinical Application of Risk Classification Model Based on Molecular Typing of Medulloblastoma in Children | not yet recruiting | — | 350 | Beijing Tiantan HospitalOTHER | 0 | Feb 8, 2023 | clinicaltrials |
| NCT05672043 | Genetic and Molecular Risk Profiles of Pediatric Malignant Brain Tumors in China(GRIPP) | recruiting | — | 400 | Beijing Tiantan HospitalOTHER | 1 | Jan 5, 2023 |
| clinicaltrials |
| NCT05641220 | Biopsy Versus Resection in Elderly Glioblastoma Patients. A Prospective Cohort Study.(BIOPSY) | not yet recruiting | — | 325 | Erasmus Medical CenterOTHER | 1 | Dec 7, 2022 | clinicaltrials |
| NCT05600660 | Orelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System Lymphoma | recruiting | Phase 2 | 28 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT03071874 | Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas | active not recruiting | Phase 2 | 28 | Massachusetts General HospitalOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT05502991 | Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma | not yet recruiting | Phase 2 | 60 | Henan Provincial People's HospitalOTHER | 1 | Sep 27, 2022 | clinicaltrials |
| NCT05512351 | Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma | recruiting | Phase 2 | 80 | Henan Provincial People's HospitalOTHER | 1 | Sep 27, 2022 | clinicaltrials |
| NCT05532969 | Correlation Between Psychological Stress and Progression of Diffuse Astrocytoma Towards Secondary Glioma | not yet recruiting | — | 60 | Henan Provincial People's HospitalOTHER | 1 | Sep 27, 2022 | clinicaltrials |
| NCT05536986 | Correlation Between Psychological Stress and Progression of Newly Oligodendroglioma Towards Secondary Glioma | not yet recruiting | — | 60 | Henan Provincial People's HospitalOTHER | 0 | Sep 27, 2022 | clinicaltrials |
| NCT05541042 | Radiogenomics in Glioblastoma: Correlation Between Multiparametric Imaging Biomarkers and Genetic Biomarkers | not yet recruiting | — | 50 | Henan Provincial People's HospitalOTHER | 1 | Sep 27, 2022 | clinicaltrials |
| NCT05518383 | B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 | recruiting | Phase 4 | 300 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Aug 26, 2022 | clinicaltrials |
| NCT02978677 | Proton Dose Escalation for Patients With Atypical or Anaplastic Meningiomas(PANAMA) | not yet recruiting | N/A | 90 | Technische Universität DresdenOTHER | 0 | Aug 3, 2022 | clinicaltrials |
| NCT05263466 | Establishing Radiolabelled PSMA as a Target for Glioma Treatment | not yet recruiting | N/A | 30 | King's College Hospital NHS TrustOTHER | 1 | Jun 10, 2022 | clinicaltrials |
| NCT04708171 | The PROGRAM-study: Awake Mapping Versus Asleep Mapping Versus No Mapping for Glioblastoma Resections(PROGRAM) | recruiting | — | 453 | Erasmus Medical CenterOTHER | 5 | May 6, 2022 | clinicaltrials |
| NCT05347641 | Penpulimab Combined With RMA Treatment of Primary Diagnosis of Primary Central Nervous System Lymphoma | not yet recruiting | Phase 2 | 23 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Apr 26, 2022 | clinicaltrials |
| NCT05140785 | Mapping Molecular Markers of Brain Tumour Activity Using MRI | not yet recruiting | N/A | 30 | King's College Hospital NHS TrustOTHER | 1 | Mar 9, 2022 | clinicaltrials |
| NCT03787056 | Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients(ONCOPRO) | recruiting | N/A | 410 | Hospices Civils de LyonOTHER | 1 | Jul 16, 2021 | clinicaltrials |
| NCT04215211 | MR Based Survival Prediction of Glioma Patients Using Artificial Intelligence | recruiting | — | 2,500 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Feb 8, 2021 | clinicaltrials |
| NCT04215224 | Histopathology Images Based Survival Prediction of Glioma Patients Using Artificial Intelligence | recruiting | — | 3,500 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Feb 8, 2021 | clinicaltrials |
| NCT04217018 | MR Based Prediction of Molecular Pathology in Glioma Using Artificial Intelligence | recruiting | — | 3,000 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Feb 8, 2021 | clinicaltrials |
| NCT04217044 | Histopathology Images Based Prediction of Molecular Pathology in Glioma Using Artificial Intelligence | recruiting | — | 3,000 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Feb 8, 2021 | clinicaltrials |
| NCT02657785 | Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy | recruiting | Phase 2 / Phase 3 | 100 | Navy General Hospital, BeijingOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT02836158 | Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL | recruiting | Phase 2 / Phase 3 | 100 | Navy General Hospital, BeijingOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT04316039 | Radiotherapy Versus Radiotherapy Combined With Temozolomide in High-risk Low-grade Gliomas After Surgery | recruiting | Phase 2 / Phase 3 | 250 | West China HospitalOTHER | 1 | Mar 20, 2020 | clinicaltrials |
| NCT03005132 | Integrative Analysis of Human Glioblastoma Multiforme | recruiting | — | 1,000 | Shanghai 10th People's HospitalOTHER | 1 | Dec 29, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Feb 8, 2023source: clinicaltrials